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Abstract: The absorption, distribution, biotransformation and excretion of a drug involve 
its transport across cell membranes. This process is essential and influenced by the 
characteristics of the drug, especially its molecular size and shape, solubility at the site of 
its absorption, relative lipid solubility, etc. One of the progressive ways for increasing 
bioavaibility is a nanoparticle preparation technique. Cholesterol, cholestenolone and 
pregnenolone acetate as model active pharmaceutical ingredients and some of the 
commonly used excipients as nanoparticle stabilizers were used in the investigated 
precipitation method that was modified and simplified and can be used as an effective and 
an affordable technique for the preparation of nanoparticles. All 120 prepared samples 
were analyzed by means of dynamic light scattering (Nanophox). The range of the particle 
size of the determined 100 nanoparticle samples was from 1 nm to 773 nm, whereas  
82 samples contained nanoparticles of less than 200 nm. Relationships between solvents 
and used excipients and their amount are discussed. 
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1. Introduction 
For achieve the pharmacological activity of an active pharmaceutical ingredient (API), the 
solubility of the API in physiological liquids is required, so that the API can be available at the place 
of absorption. Solubility in various solvents is a characteristic property of a particular compound. The 
solubility of a compound in water correlates to a great extent with the solubility in physiological 
liquids and is the first limiting factor for good absorption and biodistribution. From the point of view 
of pharmaceutical formulations, the solubility of compounds higher than 1% can be considered as 
satisfactory. When this condition is not met, it is important to improve the solubility. Solubility is not 
the only important factor; also the solubility rate is essential. This is a physico-chemical property that 
can be influenced by crystal shape (morphology, polymorphism), particle size, properties of compound 
surface, etc. [1–3]. 
The solubility of an API can be principally influenced in two ways: (i) chemically (salt formation 
when the molecule is ionizable; other molecule modification to increase hydrophilicity; prodrug 
preparation); or (ii) by optimization of physico-chemical properties (addition of excipients, particle 
size reduction or change of polymorphic forms). There are several ways to improve API solubility 
based on addition of excipients: (i) formation of molecular complexes with solubilizers (e.g., benzoate 
sodium with caffeine) and/or with soluble salts of polybasic organic acids and hydroxy acids;  
(ii) generation of inclusion complexes with natural or synthetically modified cyclodextrins or  
(iii) application of co-solvents (such as ethanol, glycerol, propylene glycol, polyethylene glycol). 
Solubility can be also increased by addition of surfactants/tensides that create micelles in the aqueous 
medium. One more frequently used method of solubility increase is complexation of API to native or 
chemically modified polysaccharide matrixes, for example, of pectins, glucans, chitosans, celluloses, 
alginates, etc. [1–5]. 
The other possibility how to increase the solubility of an API is preparation of nanoparticles. The 
advantages of nanotechnology are as follows: (i) increased bioavailability (quick dissolution; improved 
penetration through membranes); (ii) lower doses; (iii) lower toxicity; (iv) targeted biodistribution;  
(v) reduction of influence of food on variability; vi) quicker development of formulations [2,6–9]. 
Nanoparticles less than 200 nm are of practical importance [10–15]. Nevertheless it is necessary to 
admit some disadvantages of nanoparticles, such as: (i) increased aggregation in biological systems 
due to high surface energy; (ii) poor solubility and biocompatibility of carbon nanotubes; (iii) short 
biological half-life due to fast uptake in RES; (iv) high immunogenicity; (v) acute and chronic toxicity, and 
(vi) irresponsible/unforeseeable safety problems. Especially their possible toxicity comprises a great 
problem. The toxicity is dependent on the shape and surface properties of nanoparticles, because shape 
and surface can influence nanoparticle-cell interactions as well as the rate of penetration to cells. From 
various nanoparticle forms nanotubes were found as one of the most toxic nanoparticle shapes [16–19]. 
A wide range of techniques have been developed for the preparation of nanomaterials  
[8,9,12–15,20–26]. Synthetic methods for nanoparticles are typically grouped into two categories:  
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top-down (generally dispergation processes) and bottom-up (generally precipitation processes). The 
first involves division of a massive solid into smaller portions. This approach may involve milling or 
attrition, chemical methods and volatilization of a solid followed by condensation of the volatilized 
components, e.g., high-energy ball milling, high-pressure homogenization, emulsifying technology  
and microfluidization [13–15,20–23]. The second, bottom-up, method of nanoparticle fabrication  
involves condensation of atoms or molecular entities in a gas phase or in solution such as sol-gel  
synthesis [13–15,20,24] and precipitation processes, for example, spray freezing into liquid, 
evaporative precipitation into aqueous solution, precipitation with compressed antisolvent or rapid 
expansion of supercritical solution) [13–15,20,25,26]. The latter approach is by far the most popular in 
the preparation of nanoparticles. 
The aim of this paper is preparation of nanoparticles of cholesterol-like compounds by precipitation. 
The procedure is in principle similar to the solvent evaporation process, e.g., evaporative precipitation 
into aqueous solution. Methods based on the similar approach were described recently [27–29]. The 
chosen model APIs represent poorly water soluble compounds. In this pilot screening various types of 
surface-active agents were investigated. These excipients belong to GRAS substances and were 
applied in various concentrations. This contribution is the result of our interest in primary screening  
of nanoparticle preparation. Relationships between a substance, a solvent and a used excipient  
are discussed. 
2. Results and Discussion 
All three model APIs, cholesterol (5-cholesten-3β-ol, I), cholestenolone (4-cholesten-3-one, II) and 
pregnenolone acetate (5-pregnen-3β-ol-20-one acetate, III), see Figure 1, were chosen as types of 
poorly aqueous soluble compounds [4,12]. 
Figure 1. Structures of model APIs. 
 
Used excipients represent various classes of pharmaceutical adjutants that can be utilized as 
solubility modifying compounds. Tween 80 (polysorbate 80, polyoxyethylene sorbitan monooleate) is 
a nonionic surfactant and emulsifier. Polyoxyethylene groups are hydrophilic groups, nevertheless C18 
chain of oleic acid constitutes a lipophilic group. Sodium dodecyl sulfate (SDS, sodium lauryl sulfate) 
is an anionic surfactant consisting of a C12 tail attached to a sulfate group, giving the compound the 
desired amphiphilic properties. Macrogol 6000 (polyethylene glycol, PEG) is used as an excipient in 
pharmaceutical formulations. The number represents the average molecular weight of the polyethylene 
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glycol. Carboxymethyl cellulose (CMC, carmellose) is a cellulose derivative with carboxymethyl 
groups bound to some of the hydroxyl groups of the glucopyranose monomers that make up the 
cellulose backbone. It is often used as salt-sodium carboxymethyl cellulose (SCMC). It is used as a 
viscosity modifier or thickener, and to stabilize emulsions in various products. Carboxymethyl dextran 
(CMD) is a polyanionic derivative of dextran (branched glucan composed of chains of varying 
lengths). It is supplied as the sodium salt of carboxymethyl dextran (SCMD). It is used as a stabilizer 
of proteins and other sensitive biopolymers, as a carrier for biosensor surfaces, as a stable non-toxic, non-
immunogenic additive and also is used for preparation of low-toxic derivatives with drugs and other 
pharmacologically active substances [3]. 
The concentration of excipient was chosen between 1% and 10%. The optimal concentration of 
surfactant is important for optimal particles wetting. If the concentration is too low, particles float on 
the surface. If the concentration is too high bubbles appear [30]. The polar acetone (AC) and nonpolar 
dichloromethane (DCM) were chosen as the most suitable solvents for easy dissolution of the APIs. 
All model APIs dissolved in dichloromethane and acetone (2% concentration) were added to 
aqueous solutions (1%, 3%, 5%, 10% concentration) of excipients such as Tween 80 (TW), sodium 
dodecyl sulfate (SDS), macrogol 6000 (PEG), sodium carboxymethyl cellulose (SCMC) and sodium 
carboxymethyl dextran (SCMD), i.e., with each excipient 24 samples were prepared. The final 
relations API: excipient were 1:0.5 (2%:1%), 1:1.5 (2%:3%), 1:2.5 (2%:5%), 1:5 (2%:10%). Samples 
were obtained by mixing and simultaneous evaporation of organic solvent to final 10 mL sample 
volume and then characterized by dynamic light scattering [30]. All the results are presented in Tables 1–5 
and Figures 2–6. Figures 2–6 illustrate the dependence of particle size expressed as the cumulative 
distribution x90 [nm] of the compounds I–III on the concentration [%] of an individual excipient, 
whereas in Figures A samples are grouped according to individual APIs I–III, while in Figures B 
always individual APIs are separated according to the percentage of the excipient. The particle size x90 
was used for evaluation of the method success, since this value represents 90% of the cumulative 
particle size distribution in the measured sample. 
The dispersity is a measure/degree of the homogeneity/heterogeneity of sizes of particles in a 
mixture/system. It is possible to see this feature on the width of the particle-size distribution, which is 
described as differences between cumulative distribution x10 and x90, see Tables 1–5. According to the 
results, the average relation of the cumulative distribution x10/x90 ranged from 0.6 to 0.9. It is possible 
to suppose that nanoparticles are spheres, because the size in dynamic light scattering means the 
hydrodynamic diameter of the particle. All samples were dispersed by ultrasonics directly before the 
measurement to avoid possible re-agglomeration. Stabilization of the dispersed samples was achieved 
by surfactants and by the temperature. The measuring cell was equilibrated at 25 °C, so the Brown 
motion of nanoparticles is influenced just by their size. 
From Figures 2A–6A it can be stated that particle size is not dependent on model API type but it is 
strongly influenced by the type and concentration of the utilized excipient. After summarization of all 
the results it can be concluded that from 120 prepared mixtures 100 samples contained nanoparticles 
(see Tables 1–5), from which 82 samples contained nanoparticles smaller than 200 nm (see Tables  
1–5, bolded values). Nanoparticles under 10 nm were determined in 51 samples from 82, see Tables  
1–5 (bolded values with grey background). 
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Table 1. Particle size (x10, x90 [nm]) of APIs I–III and concentration [%] of Tween 80 in 
dichloromethane (DCM) or acetone (AC). All the presented results are reported as medium 
value of four independent measurements, repeatability was up to 6%. Samples that 
contained nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by grey 
background. (S.No. = sample number). 
API/ 
Solvent 
Tween 80  
S.No. 
1% 
S.No. 
3% 
S.No.
5% 
S.No. 
10%  
x10 x90 x10 x90 x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 [n
m
] 
I/DCM 1 1 1 2 139 200 3 222 289 4 158 231 
I/AC 5 2038 2242 6 9963 10,276 7 9344 10,281 8 7 8 
II/DCM 9 218 288 10 3149 3464 11 97 189 12 18 19 
II/AC 13 14 21 14 57 81 15 9345 10,281 16 2 3 
III/DCM 17 63 94 18 91 99 19 3640 4005 20 62 79 
III/AC 21 332 366 22 2 3 23 53 77 24 12 19 
Table 2. Particle size (x10, x90 [nm]) of APIs I–III and concentration [%] of sodium 
dodecyl sulfate in dichloromethane (DCM) or acetone (AC). All the presented results are 
reported as medium value of four independent measurements, repeatability was up to 6%. 
Samples that contained nanoparticles <200 nm are bolded; nanoparticles <10 nm are 
indicated by grey background. (S.No. = sample number). 
API/ 
Solvent 
Sodium dodecyl sulfate  
S.No. 
1% 
S.No. 
3% 
S.No.
5% 
S.No. 
10% 
x10 x90 x10 x90 x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 [n
m
] 
I/DCM 25 1 2 26 61 91 27 136 186 28 286 391 
I/AC 29 503 706 30 1 1 31 195 272 32 9344 10,280 
II/DCM 33 9345 10,281 34 134 184 35 1 2 36 1001 111 
II/AC 37 24 26 38 2 3 39 18 27 40 6 9 
III/DCM 41 12 18 42 1 2 43 1 2 44 1 2 
III/AC 45 771 1083 46 4 7 47 4 7 48 1 2 
Table 3. Particle size (x10, x90 [nm]) of APIs I–III and concentration [%] of macrogol 
6000 in dichloromethane (DCM) or acetone (AC). All the presented results are reported as 
medium value of four independent measurements, repeatability was up to 6%. Samples that 
contained nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by grey 
background. (S.No. = sample number). 
API/ 
Solvent 
Macrogol 6000  
S.No. 
1% 
S.No.
3% 
S.No.
5% 
S.No. 
10%  
x10 x90 x10 x90 x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 [n
m
] 
I/DCM 49 534 773 50 15 16.86 51 179 247 52 1 2 
I/AC 53 2 2 54 3 4 55 2 3 56 193 292 
II/DCM 57 90 99 58 408 576.85 59 197 285 60 211 279 
II/AC 61 1 2 62 1 2.27 63 1 2 64 29 44 
III/DCM 65 3 4 66 2 3 67 27 30 68 1 1 
III/AC 69 2929 3222 70 3 3 71 90 99 72 6 6 
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Table 4. Particle size (x10, x90 [nm]) of APIs I–III and concentration [%] of sodium 
carboxymethyl cellulose in dichloromethane (DCM) or acetone (AC). All the presented 
results are reported as medium value of four independent measurements, repeatability was 
up to 6%. Samples that contained nanoparticles <200 nm are bolded; nanoparticles <10 nm 
are indicated by grey background. (S.No. = sample number). 
API/ 
Solvent 
Sodium carboxymethyl cellulose  
S.No. 
1% 
S.No. 
3% 
S.No.
5% 
S.No. 
10%  
x10 x90 x10 x90 x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 [n
m
] 
I/DCM 73 101 111 74 2 3 75 1 1 76 1 2 
I/AC 77 6 9 78 357 486 79 7 9 80 2 3 
II/DCM 81 90 99 82 1 2 83 3 3 84 879 1249 
II/AC 85 2 3 86 90 99 87 1 2 88 101 111 
III/DCM 89 1 2 90 8799 9987 91 1 2 92 534 731 
III/AC 93 4 6 94 9345 10,281 95 9345 10,281 96 2 2 
Table 5. Particle size (x10, x90 [nm]) of APIs I–III and concentration [%] of sodium 
carboxymethyl dextran in dichloromethane (DCM) or acetone (AC). All the presented 
results are reported as medium value of four independent measurements, repeatability  
was up to 6%. Samples Samples that contained nanoparticles <200 nm are bolded; 
nanoparticles <10 nm are indicated by grey background. (S.No. = sample number). 
API/ 
Solvent 
Sodium carboxymethyl dextran  
S.No. 
1% 
S.No. 
3% 
S.No.
5% 
S.No. 
10%  
x10 x90 x10 x90 x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 [n
m
] 
I/DCM 97 5862 8981 98 1 1 99 20 31 100 17 26 
I/AC 101 1 1 102 8 9 103 3 4 104 90 99 
II/DCM 105 209 275 106 354 422 107 9345 10,281 108 2022 3205 
II/AC 109 3 3 110 9345 10,281 111 535 729 112 1 2 
III/DCM 113 1 1 114 1 2 115 1418 1560 116 3 5 
III/AC 117 9344 10,281 118 101 111 119 5 8 120 22 24 
Figure 2. Dependence of particle size (x90 [nm]) of model APIs I–III on concentration [%] 
of Tween 80 in dichloromethane (DCM) or acetone (AC). (A) Samples are grouped 
according to APIs; (B) samples are grouped according to excipient percentage. For clarity 
sake, the values on y-axis are only to 1,000 nm. 
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Figure 3. Dependence of particle size (x90 [nm]) of model APIs I–III on concentration [%] 
of sodium dodecyl sulfate in dichloromethane (DCM) or acetone (AC). (A) Samples are 
grouped according to APIs; (B) samples are grouped according to excipient percentage. 
For clarity sake, the values on y-axis are only to 1,000 nm. 
 
Figure 4. Dependence of particle size (x90 [nm]) of model APIs I–III on concentration [%] 
of macrogol 6000 in dichloromethane (DCM) or acetone (AC). (A) Samples are grouped 
according to APIs; (B) samples are grouped according to excipient percentage. For clarity 
sake, the values on y-axis are only to 1,000 nm. 
 
Figure 5. Dependence of particle size (x90 [nm]) of model APIs I–III on concentration [%] 
of sodium carboxymethyl cellulose in dichloromethane (DCM) or acetone (AC).  
(A) Samples are grouped according to APIs; (B) samples are grouped according to 
excipient percentage. For clarity sake, the values on y-axis are only to 1,000 nm. 
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Figure 6. Dependence of particle size (x90 [nm]) of model APIs I–III on concentration [%] 
of sodium carboxymethyl dextran in dichloromethane (DCM) or acetone (AC).  
(A) Samples are grouped according to APIs; (B) samples are grouped according to 
excipient percentage. For clarity sake, the values on y-axis are only to 1,000 nm. 
 
Generally it can be stated that macrogol provided mostly nanoparticles, and sodium dodecyl sulfate 
as well as sodium carboxymethyl cellulose afforded most of nanoparticles under 200 nm; the latter 
yielded most of nanoparticles less than 10 nm. 
Table 6 summarizes results of all the samples of nanoparticles under 900 nm size depending on 
solvents and the type and amount of excipients. As the aim of this contribution is specification of 
suitable conditions for nanoparticles preparation, in Table 6 generated nanoparticles are not divided 
according to used APIs. 
Table 6. View of formed samples of nanoparticles (≤900 nm) depending on solvents and type 
and amount of excipients. (conc. = concentration, excp. = excipient, dichloromethane = DCM, 
acetone = AC, Tween 80 = TW, sodium dodecyl sulfate = SDS, macrogol 6000 = PEG, 
sodium carboxymethyl cellulose = SCMC, sodium carboxymethyl dextran = SCMD). 
Excp. 
conc./type 
DCM 
Sum 
total 
Overall 
average 
x90 [nm] 
AC 
Sum 
total 
Overall 
average 
x90 [nm] 
1% 3% 5% 10% 1% 3% 5% 10% 
number of nanop. samples number of nanop. samples 
TW 3 2 2 3 10 149 2 2 1 3 8 72 
SDS 2 3 3 3 11 90 2 3 3 2 10 106 
PEG 3 3 3 3 12 193 2 3 3 3 11 42 
SCMC 3 2 3 2 10 96 3 2 2 3 10 73 
SCMD 2 3 1 2 8 95 2 2 3 3 10 99 
Sum total 13 13 12 13 51 623 11 12 12 14 49 392 
Overall 
average 
136 123 106 145 510 
125 
127 
104 68 103 45 320 
78 
80 
In Table 6 results of all the determined nanoparticles are listed. Based on these results it can be 
stated that acetone as polar solvent is more advantageous for nanoparticle generation in case of Tween, 
macrogol and sodium carboxymethyl cellulose (significantly less nanoparticle size average (calculated 
using x90): 72, 42, 73 nm compared with DCM and approximately the same number of nanoparticle 
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samples). In case of sodium carboxymethyl dextran the number of nanoparticle samples and  
their nanoparticle size were approximately the same as when using acetone and dichloromethane  
(10-99/8-95). Dichloromethane seems to be more advantageous only in combination with sodium 
dodecyl sulphate, where smaller nanoparticles were determined (10-106/11-90). 
If the influence of excipient concentration in acetone and dichloromethane is considered, it can be 
stated that generally 10% and 3% concentrations of excipient in acetone, i.e., API:excipient ratio 1:5 
and 1:1.5, or 5% and 3% concentrations of excipient in dichloromethane, i.e., API:excipient ratio 1:2.5 
and 1:1.5, seem to be the most advantageous for maximum number of nanoparticle samples with the 
smallest nanoparticle size, see Table 6 and Figures 2B–6B. If amounts of excipients regardless organic 
solvents are considered, the most favourable concentrations are the following: sodium dodecyl 
sulphate 3% (API:excipient ratio 1:1.5) and 5% (API:excipient ratio 1:2.5), sodium carboxymethyl 
cellulose 5% (API:excipient ratio 1:2.5), Tween and sodium carboxymethyl dextran 10% (API:excipient 
ratio 1: 5) and macrogol 3–10% (API:excipient ratios 1:1.5–5). 
Based on the above discussed facts it can be concluded that macrogol 6000, sodium dodecyl 
sulphate or sodium carboxymethyl cellulose can be used as effective nanoparticle-stabilizing agents in 
API:excipient ratios 1:1.5, 1:2.5, 1:5. The polar solvent acetone is preferable to nonpolar 
dichloromethane, probably due to the fact that acetone has higher boiling point (b.p. 56 °C) than 
dichloromethane (b.p. 39 °C) and it evaporates more slowly in comparison with dichloromethane 
(dynamically and/or kinetically controlled precipitation). During slow evaporation of organic solvent 
formed API particles could be more effectively stabilized by excipients in nanoparticle size (dynamic 
process of nanoparticles generation). Results with APIs dissolved in acetone provided the number of 
nanoparticle samples comparable with dichloromethane (49/51), but the particle size of APIs dissolved 
in acetone was smaller than that of APIs dissolved in dichloromethane by third (392/623). 
3. Experimental 
3.1. General 
All substances as well as excipients were purchased from Sigma-Aldrich (Prague, Czech Republic). 
Dichloromethane was purchased from Merck (Darmstadt, Germany). Acetone was purchased from 
LachNer (Neratovice, Czech Republic). All compounds as well as solvents were of analytical grade. 
H2O-HPLC—Mili-Q Grade was used as a solvent of excipients. Particle sizes of all the final samples 
were determined using dynamic light scattering in a Sympatec Photon Cross-correlation Sensor 
Nanophox (Sympatec GmbH, System-Partikel-Technik, Clausthal-Zellerfeld, Germany), He-Ne laser 
632.8 μm, intensity max. 10 mW. The measuring cell was equilibrated at 25 °C. 
3.2. Synthesis 
3.2.1. Standardized General Procedure for Preparation of Nanoparticles 
Tween 80, sodium dodecyl sulfate (SDS), macrogol 6000 (PEG), sodium carboxymethyl cellulose 
(SCMC) and sodium carboxymethyl dextran (SCMD) were used as excipients. Each excipient (0.1 g, 
0.3 g, 0.5 g or 1.0 g) was dissolved in water (10 mL), and four solutions with concentrations 1%, 3%, 
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5% and 10% were prepared. Cholesterol, cholestenolone and pregnenolone acetate (0.2 g) were 
dissolved in dichloromethane or acetone (10 mL), i.e., 2% solutions were prepared. The solutions of 
the substances in dichloromethane (DCM) or acetone (AC) were slowly dropped (2 mL/min) to the 
aqueous solutions of excipients that were stirred (600 rpm). Then the system was stirred (600 rpm) for 
10 min at 35 °C, after which the mixtures were transferred to an ultrasonic bath in the fume chamber, 
where they were mixed again for 40 min, and simultaneously organic solvent was evaporated. The 
final volume of the aqueous sample was 10 mL. The particle size of nanonized substances in samples 
was evaluated by means of Nanophox. All samples were dispersed by ultrasonics directly before the 
measurement. Measurements were repeated four times. All presented results are reported as medium 
value of these independent measurements. Repeatability was up to 6%. The results are summarized in 
Tables 1–5 and illustrated in Figures 2–6. 
4. Conclusions 
One hundred and twenty samples of cholesterol (I), cholestenolone (II) and pregnenolone acetate (III) 
were prepared by precipitation in media Tween 80, sodium dodecyl sulfate, macrogol 6000, sodium 
carboxymethyl cellulose and sodium carboxymethyl dextran. All the samples were analyzed by a 
Nanophox spectrometer. According to the cumulative distribution x90, 100 samples contained 
nanoparticles; 82 samples contained nanoparticles <200 nm; and 51 samples contained nanoparticles 
<10 nm. The smallest nanoparticle was 1 nm, the largest size was 773 nm. The polar solvent acetone 
was more preferable than nonpolar dichloromethane. Sodium dodecyl sufate, sodium carboxymethyl 
cellulose and macrogol 6000 in concentrations 10% and 3%, i.e., API:excipient ratios 1:5, 1:1.5, 
possessed the most advantageous nanoparticle-stabilizing properties. It can be concluded that the 
investigated precipitation method can be used as an effective and an affordable technique for the 
preparation of nanoparticles. The selected conditions are convenient for formation of nanoparticles, 
and the used excipients are principally applicable as nanoparticle stabilizers. 
Acknowledgements 
This study was supported by the Czech Science Foundation—GACR P304/11/2246. 
References 
1. Kerns, E.H.; Li, D. Drug-Like Properties: Concept, Structure Design and Methods; Elsevier:  
San Diego, CA, USA, 2008. 
2. Junghanns, J.U.A.H.; Muller, R.H. Nanocrystal technology, drug delivery and clinical 
applications. Int. J. Nanomed. 2008, 3, 295–309. 
3. Komarek, P.; Rabiskova, M. Pharmaceutics, 3rd ed.; Galén: Praha, Czech Republic, 2006. 
4. Kral, V.; Oktabec, Z.; Jampilek, J.; Pekarek, T.; Proksa, B.; Dohnal, J.; Malovikova, A.; 
Ebringerova, A.; Rezacova, A. (Zentiva, a.s.). Pectin complexes of steroids and pharmaceutical 
compositions based thereon. PCT Int. Appl. WO/2011/063774 A2, 3 June 2011. 
Molecules 2012, 17 11077 
 
 
5. Kral, V.; Oktabec, Z.; Jampilek, J.; Pekarek, T.; Proksa, B.; Dohnal, J.; Malovikova, A.; 
Ebringerova, A.; Rezacova, A. (Zentiva, a.s.). Pectin complexes of sartans and pharmaceutical 
compositions based thereon. PCT Int. Appl. WO/2011/063775 A2, 3 June 2011. 
6. Bawa, R. Nanopharmaceuticals for drug delivery—A review. Drug Deliv. 2009, 3, 122–127. 
7. Mihranyan, A.; Stromme, M. Solubility of fractal nanoparticles. Surf. Sci. 2007, 601, 315–319. 
8. Sahoo, N.G.; Abbas, A.; Li, C.M. Micro/Nanoparticles design and fabrication for pharmaceutical 
drug preparation and delivery applications. Curr. Drug Ther. 2008, 3, 78–97. 
9. Vijaykumar, N.; Venkateswarlu, V.; Raviraj, P. Development of oral tablet dosage form 
incorporating drug nanoparticles. Res. J. Pharm. Biol. Chem. Sci. 2010, 1, 952–963. 
10. Konan, Y.N.; Berton, M.; Gurny, R.; Allemand, E. Enhanced photodynamic activity of  
meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur. J. 
Pharm. Sci. 2003, 18, 241–249. 
11. Kral, V.; Kralova, J.; Flieger, M.; Jampilek, J.; Rezacova, A.; Dohnal, J.; Oktabec, Z.; Zaruba, K.; 
Grunwaldova, V.; Pouckova, P.; et al. Route of drug administration in nanoparticle form to enable 
penetration through the brain blood barrier. CZ Patent Appl. PV 2011-366, 21 June 2011. 
12. Kral, V.; Rak, J.; Zagora, J.; Grunwaldova, V.; Rezacova, A.; Jampilek, J.; Kutkova, B. (Zentiva, a.s.). 
Preparation, stabilization and application of API nanoparticles for development of modern drug 
formulations. CZ Patent Appl. PV 2011-353, 13 June 2011. 
13. Bhushan, B. Handbook of Nanotechnology, Part A; Springer-Verlag: Berlin/Heidelberg, 
Germany, 2004. 
14. Rao, C.; Muller, A.; Cheetham, A.K. The Chemistry of Nanomaterials, Synthesis, Properties and 
Applications; Wiley-VCH: Weinheim, Germany, 2005. 
15. Nalwa, H.S. Encyclopedia of Nanoscience and Nanotechnology; American Scientific Publisher: 
Valencia, CA, USA, 2004–2011. 
16. Singh, S.; Nalwa, H.S. Nanotechnology and health safety—toxicity and risk assessments of 
nanostructured materials on human health. J. Nanosci. Nanotechnol. 2007, 7, 3048–3070. 
17. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. Small 2008, 4, 26–49. 
18. Suh, W.H.; Suslick, K.S.; Stucky, G.D.; Suh, Y.H. Nanotechnology, nanotoxicology, and 
neuroscience. Prog. Neurobiol. 2009, 87, 133–170. 
19. Verma, A.; Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 
6, 12–21. 
20. Raab, C.; Simko, M.; Fiedeler, U.; Nentwich, M.; Gazso, A. Production of nanoparticles and 
nanomaterials. Nano Trust Dossier. 2011, 6, 1998–7293. 
21. Zielinska-Jurek, A.; Reszczynska, J.; Grabowska, E.; Zaleska, A. Nanoparticles preparation using 
microemulsion systems. In Microemulsions—An Introduction to Properties and Applications; 
Najjar, R., Ed.; InTech: Rijeka, Croatia, 2012; pp. 229–250. 
22. Lopez-Quintela, M.A. Synthesis of nanomaterials in microemulsions: Formation mechanism and 
growth control. Curr. Opin. Coll. Int. Sci. 2003, 8, 137–144. 
23. Shah, P.; Bhalodia, D.; Shelat, P. Nanoemulsion: A pharmaceutical review. Syst. Rev. Pharm. 
2010, 1, 24–32. 
24. Sonawane, R.S.; Dongare, M.K. Sol–gel synthesis of Au/TiO2 thin films for photocatalytic 
degradation of phenol in sunlight. J. Mol. Cat. A 2006, 243, 68–76. 
Molecules 2012, 17 11078 
 
 
25. Turk, M.; Bolten, D. Formation of submicron poorly water-soluble drugs by rapid expansion of 
supercritical solution (RESS): Results for naproxen. J. Supercrit. Fluids 2010, 55, 778–785. 
26. Hezave, A.Z.; Esmaeilzadeh, F. Micronization of drug particles via RESS process. J. Supercrit. 
Fluids 2010, 52, 84–98. 
27. Sanggu, K.; Waikiong, N.; Yuancai, D.; Surajit, D.; Tan, R.B.H. Preparation and physicochemical 
characterization of trans-resveratrol nanoparticle by temperature-controlled antisolvent 
precipitation. J. Food Eng. 2012, 108, 37–44. 
28. Bayal, N.; Jeevanandam, P. Synthesis of CuO@NiO core-shell nanoparticles by homogeneous 
precipitation method. J. Alloys Comp. 2012, 537, 232–241. 
29. Chin, S.F.; Pang, S.C.; Tay, S.H. Size controlled synthesis of starch nanoparticles by a simple 
nanoprecipitation method. Carbohydr. Polym. 2011, 86, 1817–1819. 
30. Merkus, H.G. Particle Size Measurements: Fundamentals, Practice, Quality; Springer 
Science+Business Media B.V.: Dordrecht, The Netherlands, 2009. 
Sample Availability: Samples of the compounds are available from the authors. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
